Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat
Free accessResearch articleFirst published online September, 2003
Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat
Background: We have previously shown that angiotensin II type 1 receptor blockers induce cardioprotection and upregulate angiotensin II type 2 receptor during in vivo postischemicreperfusion in dogs. Whether angiotensin II type 1 receptor blockers upregulate angiotensin II type 2 receptors in rats is controversial, and whether surmountable and insurmountable angiotensin II type 1 receptor blockers exert similar protective effects during reperfused myocardial infarction is not known.
Methods: We assessed the effects of the surmountable angiotensin receptor blocker valsartan, and the insurmountable angiotensin receptor blocker irbesartan, on hemodynamics and left ventricular systolic and diastolic function (echocardiography/Doppler) in vivo and infarct size (triphenyl tetrazolium chloride method), and regional angiotensin II type 1 receptor and angiotensin II type 2 receptor expression (immunoblots) ex vivo, after anterior reperfused myocardial infarction in rats. The rats were randomized to four groups: intravenous valsartan (10 mg/kg, n = 8), irbesartan (10 mg/kg, n = 8), or saline vehicle (controls, n = 14) over 30 minutes before reperfused myocardial infarction, and sham (n = 8). Angiotensin II type 1 receptor blockade was assessed by the inhibition of angiotensin II pressor responses.
Results: Compared with the control group, both angiotensin receptor blockers significantly decreased infarct size, limited the increase in left atrial pressure, improved positive left ventricular dP/dtm,x and dP/dtm,,, improved left ventricular ejection fraction and diastolic function, and limited infarct expansion after reperfused myocardial infarction. Both angiotensin receptor blockers increased angiotensin II type 2 receptor protein in the postischemic-reperfused zone, with no change in angiotensin II type 1 receptor protein. There were no changes in the sham group.
Conclusion: The overall results indicate that the angiotensin receptor blockers valsartan and irbesartan both induce cardioprotection, limit myocardial stunning, and upregulate angiotensin II type 2 receptor protein expression after reperfused myocardial infarction in the rat. Patients who are already receiving angiotensin receptor blockers and develop acute coronary syndromes might benefit from these cardioprotective effects during reperfusion therapy.
1. Dahlof B, Devereux RB, Kjeldsen SE, et al for The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet359:995-995, 2002
2.
2. Lindholm LH, Ibsen H, Dahlof B, et al for The LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet359:1004-1004, 2002
3.
3. Brenner BM, Cooper ME, de Zeeuw D, et al for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med345:861-861, 2001
4.
4. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet355:1582-1582, 2000
5.
5. Cohn JN, Tognoni G, Glazer RD, et al. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail5:155-155, 1999
6.
6. Pitt B, Segal R, Martinez FA, et al on behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study, ELITE). Lancet349:747-747, 1997
7.
7. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation100:1056-1056, 1999
8.
8. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med345:1667-1667, 2001
9.
9. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet360:752-752, 2002
10.
10. Reimer KA, Jennings RB. The 'wavefront phenomenon' of myocardial ischemic cell death. II: Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest40:633-633, 1979
11.
11. Kim CB, Braunwald E.Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation88:2426-2426, 1993
12.
12. Jugdutt BI. Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol272:H1205-H1205, 1997
13.
13. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation100:1016-1016, 1999
14.
14. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, post-ischemic ventricular dysfunction. Circulation66:1146-1146, 1982
15.
15. Bolli R.Mechanism of myocardial stunning. Circulation82:723-723, 1990
16.
16. Ford WR, Khan MI, Jugdutt BI. Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Can J Cardiol14:73-73, 1998
17.
17. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J128:1-1, 1994
18.
18. Schwarz ER, Montino H, Fleischhauer J, et al. Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther11:687-687, 1997
19.
19. Yang BC, Phillips MI, Ambeuhl PEJ, et al. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation96:922-922, 1997
20.
20. Jalowy A, Schulz R, Dorge H, et al. Infarct size reduction by AT,-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol32:1787-1787, 1998
21.
21. Dérge H, Behrends M, Schulz R, et al. Attenuation of myocardial stunning by the AT, receptor antagonist candesartan. Basic Res Cardiol94:208-208, 1999
22.
22. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev45:205-205, 1993
23.
23. Jugdutt BI. Angiotensin II receptor blockers. In 1998 Cardiology Clinics Annual of Drug Therapy. Crawford MH (ed.). W.B. Saunders, Philadelphia, Vol 2, pp 1-17, 1998
24.
24. Nio Y, Matsubara H, Murasawa S, et al. Regulation and gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest95:46-46, 1995
25.
25. Lefroy DC, Wharton J, Crake T, et al. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol28:429-429, 1996
26.
26. Haywood GA, Gullestad L, Katsuya T, et al. AT, and AT2 angiotensin receptor gene expression in human heart failure. Circulation95:1201-1201, 1997
27.
27. Xu Y, Menon V, Jugdutt BI. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C in acutely reperfused myocardial infarction. Effect of UP2696 and losartan on AT, and AT2 receptor expression, and IP3 receptor and PKC proteins. J Renin Angiotensin Aldosterone Syst1:184-184, 2000
28.
28. Jugdutt BI, Xu Y, Balghith M, et al. Cardioprotection induced by ATlR blockade after reperfused myocardial infarction: Association with regional increase in AT2R, IP3R and PKCt, proteins and cGMP. J Cardiovasc Pharmacol Therapeut5:301-301, 2000
29.
29. Jugdutt BI, Balghith M.Enhanced regional AT2 receptor and PKCt-expression during cardioprotection induced by AT, receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst2:134-140, 2001
30.
30. Horiuchi M, Akishita M, Dzau VJ. Recent progress in Angiotensin II type 2 receptor research in the cardiovascular system. Hypertension33:613-613, 1999
31.
31. Regitz-Zagrosek V, Auch-Shwelk W, Neuss M, et al. Regulation of angiotensin receptor subtypes in cell cultures, animal models and human diseases. Eur Heart J15:92-92, 1994
32.
32. Xu Y, Kumar D, Dyck J, et al. AT, and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol282:H1206-H1206, 2002
33.
33. Moudgil R, Musat-Marcu S, Xu Y, et al. Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT,R blockade. Can J Cardiol18:1107-1107, 2002
34.
34. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res28:1623-1623, 1994
35.
35. Vanderheyden PML, Fierens FLP, De Backer JP, et al. Distinction between surmountable and insurmountable selective AT, receptor antagonists by use of CHO-KI cells expressing human angiotensin II AT, receptors. Br J Pharmacol126:1057-1057, 1999
36.
36. Ojima M, Inada Y, Shibouta Y, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT, receptor. Eur J Pharmacol319:137-137, 1997
37.
37. Jugdutt BI, Joljart MJ, Khan MI. Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: Mechanistic insights into ventricular remodeling. Circulation94:94-94, 1996
38.
38. Matsumura K, Jeremy RW, Schaper J, et al. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation97:795-795, 1998
39.
39. Criscione L, de Gasparo M, Buhlmayer P, et al. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT,-receptor subtype. Br J Pharmacol110:761-761, 1993
40.
40. Culman J, von Heyer C, Piepenburg B, et al. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol367:255-255, 1999
41.
41. Lo HM, Kloner RA, Braunwald E.Effect of intracoronary verapamil on infarct size in the ischemic, reperfused canine heart: Critical importance of the timing of treatment. Am J Cardiol56:672-672, 1985
42.
42. Fishbein MC, Meerbaum S, Rit J, et al. Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J101:593-593, 1981
43.
43. Slama M, Susic D, Varagic J, et al. Echocardiographic measurement of cardiac output in rats. Am J Physiol284:H691-H691, 2003
44.
44. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of type II diabetic rat model. Circulation101:899-899, 2000
45.
45. Feigenbaum H, Popp RL, Wolfe SB, et al. Ultrasound measurements of the left ventricle. A correlative study with angiocardiography. Arch Intern Med129:461-461, 1972
46.
46. Lewis RP, Sandler H.Relationship between changes in left ventricular dimensions and the ejection fraction in man. Circulation44:548-548, 1971
47.
47. Murray JA, Johnston W, Reid JM. Echocardiographic determination of left ventricular dimensions, volumes and performance. Am J Cardiol30:252-252, 1972
48.
48. Belenkie I, Nutter DO, Clark DW, et al. Assessment of left ventricular dimensions and function by echocardiography. Am J Cardiol31:755-755, 1973
49.
49. Balghith M, Jugdutt BI. Assessment of diastolic dysfunction after acute myocardial infarction using Doppler Echocardiography. Can J Cardiol18:69-69, 2001
50.
50. Ping P, Takano H, Zhang J, et al. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits. A signaling mechanism for both nitricoxide-induced and ischemia-induced preconditioning. Circ Res84:587-587, 1999
51.
51. Richard V, Murry CE, Reimer KA. Healing of myocardial infarcts in dogs. Effects of late reperfusion. Circulation92:1891-1891, 1995
52.
52. Jugdutt BI, Khan MI, Jugdutt SJ, et al. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation92:926-926, 1995
53.
53. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin type 2 receptors. J Clin Invest99:1926-1926, 1997
54.
54. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension31:349-349, 1998
55.
55. Youhua Z, Shouchun X.Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac renin-angiotensin system. Chin Med J108:28-28, 1995
56.
56. Urata HB, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing hearts. Circ Res66:883-883, 1990
57.
57. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA93:156-156, 1996
58.
58. Fliss H, Gattinger D.Apoptosis in ischemic and reperfusion rat myocardium. Circ Res79:949-949, 1996
59.
59. Moudgil R, Menon V, Xu Y, et al. Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in working rat hearts. J of Hypertension19:1121-1121, 2001
60.
60. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro.J Moll Cell Cardiol29:859-859, 1997
61.
61. Baily RG, Lehman JC, Gubin SS, et al. Noninvasive assessment of ventricular damage in rats with myocardial infarction. Cardiovasc Res27:851-855, 1993
62.
62. Litwin SE, Katz SE, Weinberg EO, et al. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation91:2642-2654, 1995
63.
63. Hoit BD, Castro C, Bultron G, et al. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail5:324-333, 1999
64.
64. Manning WJ, Wei JY, Katz SE, et al. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: Necropsy validation. Am J Physiol266:H1672-H1675, 1994
